Mesothelioma :: risk factors, treatment and prognosis /
"Mesothelioma is a type of cancer in which tumors form in the tissue that lines the lungs, heart, stomach, and other organs. While mesothelioma is relatively rare, it represents a serious health crisis as the disease is aggressive and often fatal. This book includes five chapters that detail th...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
New York :
Nova Science Publishers,
[2021]
|
| Schriftenreihe: | Cancer etiology, diagnosis and treatments
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | "Mesothelioma is a type of cancer in which tumors form in the tissue that lines the lungs, heart, stomach, and other organs. While mesothelioma is relatively rare, it represents a serious health crisis as the disease is aggressive and often fatal. This book includes five chapters that detail the treatment and prognosis of the disease as well as the factors that put a person at risk for developing mesothelioma. Chapter One describes the most promising emerging immunotherapy combinations for the treatment of malignant pleural mesothelioma, discussing the biological rational underlying their development as well as the issues surrounding their clinical development. Chapter Two provides an overview of malignant mesothelioma, describing the history of its diagnosis and treatment as well as the role that asbestos exposure and other factors play in its development. Chapter Three revises the role of the main inflammatory and immunological markers as prognostic indicators in malignant pleural mesothelioma and discusses the surgical effects on immune response against cancer. Chapter Four explores the main cancer markers utilized for mesothelioma diagnosis as well as the new developments in the field. Lastly, Chapter Five examines the various surgical options available for removing pleural tumors"-- |
| Beschreibung: | 1 online resource. |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 1685071341 9781685071349 |
Internformat
MARC
| LEADER | 00000cam a22000008i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1267337746 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 210914s2021 nyu ob 001 0 eng | ||
| 010 | |a 2021044658 | ||
| 040 | |a DLC |b eng |e rda |c DLC |d OCLCO |d OCLCF |d OCLCO |d N$T |d OCLCQ |d QGK |d OCLCO | ||
| 020 | |a 1685071341 | ||
| 020 | |a 9781685071349 |q (electronic bk.) | ||
| 020 | |z 9781685070755 |q (paperback) | ||
| 035 | |a (OCoLC)1267337746 | ||
| 042 | |a pcc | ||
| 050 | 0 | 0 | |a RC280.L8 |
| 082 | 7 | |a 616.99/424 |2 23 | |
| 049 | |a MAIN | ||
| 245 | 0 | 0 | |a Mesothelioma : |b risk factors, treatment and prognosis / |c Albert K. Martin, editor. |
| 263 | |a 2111 | ||
| 264 | 1 | |a New York : |b Nova Science Publishers, |c [2021] | |
| 300 | |a 1 online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 0 | |a Cancer etiology, diagnosis and treatments | |
| 504 | |a Includes bibliographical references and index. | ||
| 520 | |a "Mesothelioma is a type of cancer in which tumors form in the tissue that lines the lungs, heart, stomach, and other organs. While mesothelioma is relatively rare, it represents a serious health crisis as the disease is aggressive and often fatal. This book includes five chapters that detail the treatment and prognosis of the disease as well as the factors that put a person at risk for developing mesothelioma. Chapter One describes the most promising emerging immunotherapy combinations for the treatment of malignant pleural mesothelioma, discussing the biological rational underlying their development as well as the issues surrounding their clinical development. Chapter Two provides an overview of malignant mesothelioma, describing the history of its diagnosis and treatment as well as the role that asbestos exposure and other factors play in its development. Chapter Three revises the role of the main inflammatory and immunological markers as prognostic indicators in malignant pleural mesothelioma and discusses the surgical effects on immune response against cancer. Chapter Four explores the main cancer markers utilized for mesothelioma diagnosis as well as the new developments in the field. Lastly, Chapter Five examines the various surgical options available for removing pleural tumors"-- |c Provided by publisher. | ||
| 588 | |a Description based on print version record and CIP data provided by publisher; resource not viewed. | ||
| 505 | 0 | |a Intro -- Contents -- Preface -- Chapter 1 -- Mesothelioma: The Advent of Immunotherapy -- Abstract -- Introduction -- Rationale: Immune Cells Orchestra inside Mesothelioma Tumor Microenvironment -- Immune Check-Point Inhibitors -- Brief History of Immunotherapy in Malignant Pleural Mesothelioma -- Advent of Immune Checkpoint Inhibitors -- Checkpoint Inhibitor within the Salvage Setting -- Anti-CTLA4 -- Anti-PD1 -- Anti PD-L1 -- Combination of Checkpoint Inhibitors -- Checkpoint Inhibitors within the First-Line Setting -- Combination of Checkpoint Inhibitors -- Other Immunotherapies -- Vaccines -- Cellular Immunotherapy -- Conclusion -- References -- Chapter 2 -- Malignant Mesothelioma -- Abstract -- Introduction -- Risk Factors -- Asbestos -- People Most at Risk of an Asbestos-Related Disease -- Non-Occupational Exposure -- Histopathology and Pathophysiology -- Presentation -- Evaluation -- Treatment -- Preventive Measures -- Curative Measures -- Surgical -- Malignant Mesothelioma of Tunica Vaginalis -- Malignant Pleural Mesothelioma -- Chemotherapy -- Radiotherapy -- Recommendation -- Targeted Therapy -- Gene Therapy -- Photodynamic Therapy -- Immunotherapy -- Virus Therapies -- Prognosis -- References -- Chapter 3 -- Inflammatory and Immunological Aspects in the Surgical Management of Malignant Pleural Mesothelioma -- Abstract -- Introduction -- Prognostic Role of Inflammatory and Immunological Markers -- Blood -- Platelets Count -- White Blood Cell Count -- White Blood Cell Differential -- Hemoglobin -- Red Cell Distribution Width (RDW) -- Ratios -- Neutrophil-to-Lymphocyte Ratio -- Platelet-to-Lymphocyte Ratio -- Lymphocyte-to-Monocyte Ratio (LMR) -- Osteopontin (OPN) -- Prognostic Groups -- Cancer and Leukemia Group B -- European Organization for Research and Treatment of Cancer (EORTC) -- Modified Glasgow Prognostic Score (mGPS). | |
| 505 | 8 | |a Prognostic Risk Classification (PRC) -- Effects of Inflammation on Quality of Life -- Surgery Related Inflammatory and Immune Impairment in Cancer -- Conclusion -- References -- Biographical Sketch -- Chapter 4 -- New Developments in Mesothelioma Markers -- Abstract -- Introduction -- Malignant Mesothelioma -- Asbestos -- Cancer Markers -- Biochemical Indicators Linked to Cancer Development -- Cancer Markers in Malignant Mesothelioma -- Immunochemical Markers -- Genetic Markers -- Soluble Markers of Mesothelioma -- Mesothelin -- Fibulin-3 -- Osteopontin and RANTES -- New Biomarkers -- Epigenetics and miRNA -- Conclusion -- References -- Chapter 5 -- Surgical Approaches to Pleural Tumours -- Abstract -- Introduction -- Benign Tumours -- Clinical Presentation -- Diagnosis -- Therapy -- Malignant Tumours -- Epidemiology and Aetiology -- Exposure to Asbestos -- Other Risk Factors -- Clinical Presentation -- Diagnosis -- Chest X-Ray -- Chest CT Scan with Contrast Enhancement -- 18-Fluorodeoxyglucose Positron Emission Tomography with (18FDG-PET) -- Magnetic Resonance Imaging (MRI) -- Other Radiological Methods -- Tumour Marker Evaluation in Pleural Fluid -- Cytological Examination of Pleural Fluid -- Pathological Anatomy -- Prognosis and Staging -- Treatment -- References -- Index -- Blank Page. | |
| 650 | 0 | |a Mesothelioma. |0 http://id.loc.gov/authorities/subjects/sh85083965 | |
| 650 | 2 | |a Mesothelioma |0 https://id.nlm.nih.gov/mesh/D008654 | |
| 650 | 6 | |a Mésothéliome. | |
| 650 | 7 | |a Mesothelioma |2 fast | |
| 700 | 1 | |a Martin, Albert K., |e editor. | |
| 776 | 0 | 8 | |i Print version: |t Mesothelioma |d New York : Nova Science Publishers, [2021] |z 9781685070755 |w (DLC) 2021044657 |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3021544 |3 Volltext |
| 938 | |a YBP Library Services |b YANK |n 302445682 | ||
| 938 | |a EBSCOhost |b EBSC |n 3021544 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1267337746 |
|---|---|
| _version_ | 1816882549684699136 |
| adam_text | |
| any_adam_object | |
| author2 | Martin, Albert K. |
| author2_role | edt |
| author2_variant | a k m ak akm |
| author_facet | Martin, Albert K. |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RC280 |
| callnumber-raw | RC280.L8 |
| callnumber-search | RC280.L8 |
| callnumber-sort | RC 3280 L8 |
| callnumber-subject | RC - Internal Medicine |
| collection | ZDB-4-EBA |
| contents | Intro -- Contents -- Preface -- Chapter 1 -- Mesothelioma: The Advent of Immunotherapy -- Abstract -- Introduction -- Rationale: Immune Cells Orchestra inside Mesothelioma Tumor Microenvironment -- Immune Check-Point Inhibitors -- Brief History of Immunotherapy in Malignant Pleural Mesothelioma -- Advent of Immune Checkpoint Inhibitors -- Checkpoint Inhibitor within the Salvage Setting -- Anti-CTLA4 -- Anti-PD1 -- Anti PD-L1 -- Combination of Checkpoint Inhibitors -- Checkpoint Inhibitors within the First-Line Setting -- Combination of Checkpoint Inhibitors -- Other Immunotherapies -- Vaccines -- Cellular Immunotherapy -- Conclusion -- References -- Chapter 2 -- Malignant Mesothelioma -- Abstract -- Introduction -- Risk Factors -- Asbestos -- People Most at Risk of an Asbestos-Related Disease -- Non-Occupational Exposure -- Histopathology and Pathophysiology -- Presentation -- Evaluation -- Treatment -- Preventive Measures -- Curative Measures -- Surgical -- Malignant Mesothelioma of Tunica Vaginalis -- Malignant Pleural Mesothelioma -- Chemotherapy -- Radiotherapy -- Recommendation -- Targeted Therapy -- Gene Therapy -- Photodynamic Therapy -- Immunotherapy -- Virus Therapies -- Prognosis -- References -- Chapter 3 -- Inflammatory and Immunological Aspects in the Surgical Management of Malignant Pleural Mesothelioma -- Abstract -- Introduction -- Prognostic Role of Inflammatory and Immunological Markers -- Blood -- Platelets Count -- White Blood Cell Count -- White Blood Cell Differential -- Hemoglobin -- Red Cell Distribution Width (RDW) -- Ratios -- Neutrophil-to-Lymphocyte Ratio -- Platelet-to-Lymphocyte Ratio -- Lymphocyte-to-Monocyte Ratio (LMR) -- Osteopontin (OPN) -- Prognostic Groups -- Cancer and Leukemia Group B -- European Organization for Research and Treatment of Cancer (EORTC) -- Modified Glasgow Prognostic Score (mGPS). Prognostic Risk Classification (PRC) -- Effects of Inflammation on Quality of Life -- Surgery Related Inflammatory and Immune Impairment in Cancer -- Conclusion -- References -- Biographical Sketch -- Chapter 4 -- New Developments in Mesothelioma Markers -- Abstract -- Introduction -- Malignant Mesothelioma -- Asbestos -- Cancer Markers -- Biochemical Indicators Linked to Cancer Development -- Cancer Markers in Malignant Mesothelioma -- Immunochemical Markers -- Genetic Markers -- Soluble Markers of Mesothelioma -- Mesothelin -- Fibulin-3 -- Osteopontin and RANTES -- New Biomarkers -- Epigenetics and miRNA -- Conclusion -- References -- Chapter 5 -- Surgical Approaches to Pleural Tumours -- Abstract -- Introduction -- Benign Tumours -- Clinical Presentation -- Diagnosis -- Therapy -- Malignant Tumours -- Epidemiology and Aetiology -- Exposure to Asbestos -- Other Risk Factors -- Clinical Presentation -- Diagnosis -- Chest X-Ray -- Chest CT Scan with Contrast Enhancement -- 18-Fluorodeoxyglucose Positron Emission Tomography with (18FDG-PET) -- Magnetic Resonance Imaging (MRI) -- Other Radiological Methods -- Tumour Marker Evaluation in Pleural Fluid -- Cytological Examination of Pleural Fluid -- Pathological Anatomy -- Prognosis and Staging -- Treatment -- References -- Index -- Blank Page. |
| ctrlnum | (OCoLC)1267337746 |
| dewey-full | 616.99/424 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/424 |
| dewey-search | 616.99/424 |
| dewey-sort | 3616.99 3424 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06306cam a22004938i 4500</leader><controlfield tag="001">ZDB-4-EBA-on1267337746</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">210914s2021 nyu ob 001 0 eng </controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a"> 2021044658</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DLC</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">DLC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">N$T</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">QGK</subfield><subfield code="d">OCLCO</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1685071341</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781685071349</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781685070755</subfield><subfield code="q">(paperback)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1267337746</subfield></datafield><datafield tag="042" ind1=" " ind2=" "><subfield code="a">pcc</subfield></datafield><datafield tag="050" ind1="0" ind2="0"><subfield code="a">RC280.L8</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">616.99/424</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Mesothelioma :</subfield><subfield code="b">risk factors, treatment and prognosis /</subfield><subfield code="c">Albert K. Martin, editor.</subfield></datafield><datafield tag="263" ind1=" " ind2=" "><subfield code="a">2111</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York :</subfield><subfield code="b">Nova Science Publishers,</subfield><subfield code="c">[2021]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Cancer etiology, diagnosis and treatments</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">"Mesothelioma is a type of cancer in which tumors form in the tissue that lines the lungs, heart, stomach, and other organs. While mesothelioma is relatively rare, it represents a serious health crisis as the disease is aggressive and often fatal. This book includes five chapters that detail the treatment and prognosis of the disease as well as the factors that put a person at risk for developing mesothelioma. Chapter One describes the most promising emerging immunotherapy combinations for the treatment of malignant pleural mesothelioma, discussing the biological rational underlying their development as well as the issues surrounding their clinical development. Chapter Two provides an overview of malignant mesothelioma, describing the history of its diagnosis and treatment as well as the role that asbestos exposure and other factors play in its development. Chapter Three revises the role of the main inflammatory and immunological markers as prognostic indicators in malignant pleural mesothelioma and discusses the surgical effects on immune response against cancer. Chapter Four explores the main cancer markers utilized for mesothelioma diagnosis as well as the new developments in the field. Lastly, Chapter Five examines the various surgical options available for removing pleural tumors"--</subfield><subfield code="c">Provided by publisher.</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on print version record and CIP data provided by publisher; resource not viewed.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Intro -- Contents -- Preface -- Chapter 1 -- Mesothelioma: The Advent of Immunotherapy -- Abstract -- Introduction -- Rationale: Immune Cells Orchestra inside Mesothelioma Tumor Microenvironment -- Immune Check-Point Inhibitors -- Brief History of Immunotherapy in Malignant Pleural Mesothelioma -- Advent of Immune Checkpoint Inhibitors -- Checkpoint Inhibitor within the Salvage Setting -- Anti-CTLA4 -- Anti-PD1 -- Anti PD-L1 -- Combination of Checkpoint Inhibitors -- Checkpoint Inhibitors within the First-Line Setting -- Combination of Checkpoint Inhibitors -- Other Immunotherapies -- Vaccines -- Cellular Immunotherapy -- Conclusion -- References -- Chapter 2 -- Malignant Mesothelioma -- Abstract -- Introduction -- Risk Factors -- Asbestos -- People Most at Risk of an Asbestos-Related Disease -- Non-Occupational Exposure -- Histopathology and Pathophysiology -- Presentation -- Evaluation -- Treatment -- Preventive Measures -- Curative Measures -- Surgical -- Malignant Mesothelioma of Tunica Vaginalis -- Malignant Pleural Mesothelioma -- Chemotherapy -- Radiotherapy -- Recommendation -- Targeted Therapy -- Gene Therapy -- Photodynamic Therapy -- Immunotherapy -- Virus Therapies -- Prognosis -- References -- Chapter 3 -- Inflammatory and Immunological Aspects in the Surgical Management of Malignant Pleural Mesothelioma -- Abstract -- Introduction -- Prognostic Role of Inflammatory and Immunological Markers -- Blood -- Platelets Count -- White Blood Cell Count -- White Blood Cell Differential -- Hemoglobin -- Red Cell Distribution Width (RDW) -- Ratios -- Neutrophil-to-Lymphocyte Ratio -- Platelet-to-Lymphocyte Ratio -- Lymphocyte-to-Monocyte Ratio (LMR) -- Osteopontin (OPN) -- Prognostic Groups -- Cancer and Leukemia Group B -- European Organization for Research and Treatment of Cancer (EORTC) -- Modified Glasgow Prognostic Score (mGPS).</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Prognostic Risk Classification (PRC) -- Effects of Inflammation on Quality of Life -- Surgery Related Inflammatory and Immune Impairment in Cancer -- Conclusion -- References -- Biographical Sketch -- Chapter 4 -- New Developments in Mesothelioma Markers -- Abstract -- Introduction -- Malignant Mesothelioma -- Asbestos -- Cancer Markers -- Biochemical Indicators Linked to Cancer Development -- Cancer Markers in Malignant Mesothelioma -- Immunochemical Markers -- Genetic Markers -- Soluble Markers of Mesothelioma -- Mesothelin -- Fibulin-3 -- Osteopontin and RANTES -- New Biomarkers -- Epigenetics and miRNA -- Conclusion -- References -- Chapter 5 -- Surgical Approaches to Pleural Tumours -- Abstract -- Introduction -- Benign Tumours -- Clinical Presentation -- Diagnosis -- Therapy -- Malignant Tumours -- Epidemiology and Aetiology -- Exposure to Asbestos -- Other Risk Factors -- Clinical Presentation -- Diagnosis -- Chest X-Ray -- Chest CT Scan with Contrast Enhancement -- 18-Fluorodeoxyglucose Positron Emission Tomography with (18FDG-PET) -- Magnetic Resonance Imaging (MRI) -- Other Radiological Methods -- Tumour Marker Evaluation in Pleural Fluid -- Cytological Examination of Pleural Fluid -- Pathological Anatomy -- Prognosis and Staging -- Treatment -- References -- Index -- Blank Page.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Mesothelioma.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85083965</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Mesothelioma</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D008654</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Mésothéliome.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Mesothelioma</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Martin, Albert K.,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="t">Mesothelioma</subfield><subfield code="d">New York : Nova Science Publishers, [2021]</subfield><subfield code="z">9781685070755</subfield><subfield code="w">(DLC) 2021044657</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3021544</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">302445682</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">3021544</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-on1267337746 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:30:23Z |
| institution | BVB |
| isbn | 1685071341 9781685071349 |
| language | English |
| lccn | 2021044658 |
| oclc_num | 1267337746 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource. |
| psigel | ZDB-4-EBA |
| publishDate | 2021 |
| publishDateSearch | 2021 |
| publishDateSort | 2021 |
| publisher | Nova Science Publishers, |
| record_format | marc |
| series2 | Cancer etiology, diagnosis and treatments |
| spelling | Mesothelioma : risk factors, treatment and prognosis / Albert K. Martin, editor. 2111 New York : Nova Science Publishers, [2021] 1 online resource. text txt rdacontent computer c rdamedia online resource cr rdacarrier Cancer etiology, diagnosis and treatments Includes bibliographical references and index. "Mesothelioma is a type of cancer in which tumors form in the tissue that lines the lungs, heart, stomach, and other organs. While mesothelioma is relatively rare, it represents a serious health crisis as the disease is aggressive and often fatal. This book includes five chapters that detail the treatment and prognosis of the disease as well as the factors that put a person at risk for developing mesothelioma. Chapter One describes the most promising emerging immunotherapy combinations for the treatment of malignant pleural mesothelioma, discussing the biological rational underlying their development as well as the issues surrounding their clinical development. Chapter Two provides an overview of malignant mesothelioma, describing the history of its diagnosis and treatment as well as the role that asbestos exposure and other factors play in its development. Chapter Three revises the role of the main inflammatory and immunological markers as prognostic indicators in malignant pleural mesothelioma and discusses the surgical effects on immune response against cancer. Chapter Four explores the main cancer markers utilized for mesothelioma diagnosis as well as the new developments in the field. Lastly, Chapter Five examines the various surgical options available for removing pleural tumors"-- Provided by publisher. Description based on print version record and CIP data provided by publisher; resource not viewed. Intro -- Contents -- Preface -- Chapter 1 -- Mesothelioma: The Advent of Immunotherapy -- Abstract -- Introduction -- Rationale: Immune Cells Orchestra inside Mesothelioma Tumor Microenvironment -- Immune Check-Point Inhibitors -- Brief History of Immunotherapy in Malignant Pleural Mesothelioma -- Advent of Immune Checkpoint Inhibitors -- Checkpoint Inhibitor within the Salvage Setting -- Anti-CTLA4 -- Anti-PD1 -- Anti PD-L1 -- Combination of Checkpoint Inhibitors -- Checkpoint Inhibitors within the First-Line Setting -- Combination of Checkpoint Inhibitors -- Other Immunotherapies -- Vaccines -- Cellular Immunotherapy -- Conclusion -- References -- Chapter 2 -- Malignant Mesothelioma -- Abstract -- Introduction -- Risk Factors -- Asbestos -- People Most at Risk of an Asbestos-Related Disease -- Non-Occupational Exposure -- Histopathology and Pathophysiology -- Presentation -- Evaluation -- Treatment -- Preventive Measures -- Curative Measures -- Surgical -- Malignant Mesothelioma of Tunica Vaginalis -- Malignant Pleural Mesothelioma -- Chemotherapy -- Radiotherapy -- Recommendation -- Targeted Therapy -- Gene Therapy -- Photodynamic Therapy -- Immunotherapy -- Virus Therapies -- Prognosis -- References -- Chapter 3 -- Inflammatory and Immunological Aspects in the Surgical Management of Malignant Pleural Mesothelioma -- Abstract -- Introduction -- Prognostic Role of Inflammatory and Immunological Markers -- Blood -- Platelets Count -- White Blood Cell Count -- White Blood Cell Differential -- Hemoglobin -- Red Cell Distribution Width (RDW) -- Ratios -- Neutrophil-to-Lymphocyte Ratio -- Platelet-to-Lymphocyte Ratio -- Lymphocyte-to-Monocyte Ratio (LMR) -- Osteopontin (OPN) -- Prognostic Groups -- Cancer and Leukemia Group B -- European Organization for Research and Treatment of Cancer (EORTC) -- Modified Glasgow Prognostic Score (mGPS). Prognostic Risk Classification (PRC) -- Effects of Inflammation on Quality of Life -- Surgery Related Inflammatory and Immune Impairment in Cancer -- Conclusion -- References -- Biographical Sketch -- Chapter 4 -- New Developments in Mesothelioma Markers -- Abstract -- Introduction -- Malignant Mesothelioma -- Asbestos -- Cancer Markers -- Biochemical Indicators Linked to Cancer Development -- Cancer Markers in Malignant Mesothelioma -- Immunochemical Markers -- Genetic Markers -- Soluble Markers of Mesothelioma -- Mesothelin -- Fibulin-3 -- Osteopontin and RANTES -- New Biomarkers -- Epigenetics and miRNA -- Conclusion -- References -- Chapter 5 -- Surgical Approaches to Pleural Tumours -- Abstract -- Introduction -- Benign Tumours -- Clinical Presentation -- Diagnosis -- Therapy -- Malignant Tumours -- Epidemiology and Aetiology -- Exposure to Asbestos -- Other Risk Factors -- Clinical Presentation -- Diagnosis -- Chest X-Ray -- Chest CT Scan with Contrast Enhancement -- 18-Fluorodeoxyglucose Positron Emission Tomography with (18FDG-PET) -- Magnetic Resonance Imaging (MRI) -- Other Radiological Methods -- Tumour Marker Evaluation in Pleural Fluid -- Cytological Examination of Pleural Fluid -- Pathological Anatomy -- Prognosis and Staging -- Treatment -- References -- Index -- Blank Page. Mesothelioma. http://id.loc.gov/authorities/subjects/sh85083965 Mesothelioma https://id.nlm.nih.gov/mesh/D008654 Mésothéliome. Mesothelioma fast Martin, Albert K., editor. Print version: Mesothelioma New York : Nova Science Publishers, [2021] 9781685070755 (DLC) 2021044657 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3021544 Volltext |
| spellingShingle | Mesothelioma : risk factors, treatment and prognosis / Intro -- Contents -- Preface -- Chapter 1 -- Mesothelioma: The Advent of Immunotherapy -- Abstract -- Introduction -- Rationale: Immune Cells Orchestra inside Mesothelioma Tumor Microenvironment -- Immune Check-Point Inhibitors -- Brief History of Immunotherapy in Malignant Pleural Mesothelioma -- Advent of Immune Checkpoint Inhibitors -- Checkpoint Inhibitor within the Salvage Setting -- Anti-CTLA4 -- Anti-PD1 -- Anti PD-L1 -- Combination of Checkpoint Inhibitors -- Checkpoint Inhibitors within the First-Line Setting -- Combination of Checkpoint Inhibitors -- Other Immunotherapies -- Vaccines -- Cellular Immunotherapy -- Conclusion -- References -- Chapter 2 -- Malignant Mesothelioma -- Abstract -- Introduction -- Risk Factors -- Asbestos -- People Most at Risk of an Asbestos-Related Disease -- Non-Occupational Exposure -- Histopathology and Pathophysiology -- Presentation -- Evaluation -- Treatment -- Preventive Measures -- Curative Measures -- Surgical -- Malignant Mesothelioma of Tunica Vaginalis -- Malignant Pleural Mesothelioma -- Chemotherapy -- Radiotherapy -- Recommendation -- Targeted Therapy -- Gene Therapy -- Photodynamic Therapy -- Immunotherapy -- Virus Therapies -- Prognosis -- References -- Chapter 3 -- Inflammatory and Immunological Aspects in the Surgical Management of Malignant Pleural Mesothelioma -- Abstract -- Introduction -- Prognostic Role of Inflammatory and Immunological Markers -- Blood -- Platelets Count -- White Blood Cell Count -- White Blood Cell Differential -- Hemoglobin -- Red Cell Distribution Width (RDW) -- Ratios -- Neutrophil-to-Lymphocyte Ratio -- Platelet-to-Lymphocyte Ratio -- Lymphocyte-to-Monocyte Ratio (LMR) -- Osteopontin (OPN) -- Prognostic Groups -- Cancer and Leukemia Group B -- European Organization for Research and Treatment of Cancer (EORTC) -- Modified Glasgow Prognostic Score (mGPS). Prognostic Risk Classification (PRC) -- Effects of Inflammation on Quality of Life -- Surgery Related Inflammatory and Immune Impairment in Cancer -- Conclusion -- References -- Biographical Sketch -- Chapter 4 -- New Developments in Mesothelioma Markers -- Abstract -- Introduction -- Malignant Mesothelioma -- Asbestos -- Cancer Markers -- Biochemical Indicators Linked to Cancer Development -- Cancer Markers in Malignant Mesothelioma -- Immunochemical Markers -- Genetic Markers -- Soluble Markers of Mesothelioma -- Mesothelin -- Fibulin-3 -- Osteopontin and RANTES -- New Biomarkers -- Epigenetics and miRNA -- Conclusion -- References -- Chapter 5 -- Surgical Approaches to Pleural Tumours -- Abstract -- Introduction -- Benign Tumours -- Clinical Presentation -- Diagnosis -- Therapy -- Malignant Tumours -- Epidemiology and Aetiology -- Exposure to Asbestos -- Other Risk Factors -- Clinical Presentation -- Diagnosis -- Chest X-Ray -- Chest CT Scan with Contrast Enhancement -- 18-Fluorodeoxyglucose Positron Emission Tomography with (18FDG-PET) -- Magnetic Resonance Imaging (MRI) -- Other Radiological Methods -- Tumour Marker Evaluation in Pleural Fluid -- Cytological Examination of Pleural Fluid -- Pathological Anatomy -- Prognosis and Staging -- Treatment -- References -- Index -- Blank Page. Mesothelioma. http://id.loc.gov/authorities/subjects/sh85083965 Mesothelioma https://id.nlm.nih.gov/mesh/D008654 Mésothéliome. Mesothelioma fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85083965 https://id.nlm.nih.gov/mesh/D008654 |
| title | Mesothelioma : risk factors, treatment and prognosis / |
| title_auth | Mesothelioma : risk factors, treatment and prognosis / |
| title_exact_search | Mesothelioma : risk factors, treatment and prognosis / |
| title_full | Mesothelioma : risk factors, treatment and prognosis / Albert K. Martin, editor. |
| title_fullStr | Mesothelioma : risk factors, treatment and prognosis / Albert K. Martin, editor. |
| title_full_unstemmed | Mesothelioma : risk factors, treatment and prognosis / Albert K. Martin, editor. |
| title_short | Mesothelioma : |
| title_sort | mesothelioma risk factors treatment and prognosis |
| title_sub | risk factors, treatment and prognosis / |
| topic | Mesothelioma. http://id.loc.gov/authorities/subjects/sh85083965 Mesothelioma https://id.nlm.nih.gov/mesh/D008654 Mésothéliome. Mesothelioma fast |
| topic_facet | Mesothelioma. Mesothelioma Mésothéliome. |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3021544 |
| work_keys_str_mv | AT martinalbertk mesotheliomariskfactorstreatmentandprognosis |